Biosimilar monoclonal antibodies: Challenges and approaches towards formulation

Area of Science:

• Biopharmaceutical development
• Intellectual property in drug development

Background:

• Many biologic drugs, especially monoclonal antibodies (mAbs), have lost molecule patent protection.
• Secondary patents (formulation, manufacturing) hinder the timely market entry of affordable biosimilars.
• Innovator companies employ life cycle management strategies to delay biosimilar competition.

Purpose of the Study:

• To review key approaches in biosimilar formulation development.
• To summarize the utilization of innovator formulation knowledge for developing alternative biosimilar mAb formulations.
• To address challenges in avoiding secondary patent infringement.

Main Methods:

• Review of scientific literature and patent landscapes.
• Analysis of innovator formulation strategies and their implications for biosimilar development.
• Discussion of critical variables in alternative formulation design, including patent timelines and non-infringement.

Main Results:

• Alternative formulation development is crucial for biosimilar market entry.
• Leveraging innovator formulation knowledge can accelerate biosimilar development but incurs time and cost.
• Strategic planning is essential to navigate complex patent landscapes and project timelines.

Conclusions:

• Biosimilar companies can overcome secondary patent barriers by developing alternative formulations.
• Understanding and utilizing the innovator formulation knowledge space is a viable strategy.
• Successful biosimilar development requires careful consideration of patent expiration, non-infringement, and project timelines.